Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Hoxha M, Zappacosta B. A review on the role of fatty acids in colorectal cancer progression. Front Pharmacol. 2022;13:1032806. doi:10.3389/fphar.2022.1032806
   PubMedGoogle Scholar
• Peng X, Zhao G, Lin J, Li C. Interaction of mannose binding lectin and other pattern recognition receptors in human corneal epithelial cells during Aspergillus fumigatus infection. Int Immunopharmacol. 2018;63:161–169. doi:10.1016/j.intimp.2018.08.003
   PubMed Web of Science ®Google Scholar
• Zhang Q, Tang L, Zhou Y, He W, Li W. Immune checkpoint inhibitor-associated pneumonitis in non-small cell lung cancer: current understanding in characteristics, diagnosis, and management. Front Immunol. 2021;12:663986. doi:10.3389/fimmu.2021.663986
   PubMed Web of Science ®Google Scholar
• Lentz RW, Colton MD, Mitra SS, Messersmith WA. Innate immune checkpoint inhibitors: the next breakthrough in medical oncology? Mol Cancer Ther. 2021;20(6):961–974. doi:10.1158/1535-7163.MCT-21-0041
   PubMed Web of Science ®Google Scholar
• Dai W, Xu L, Yu X, et al. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism. J Hepatol. 2020;72(5):909–923. doi:10.1016/j.jhep.2019.12.015
   PubMed Web of Science ®Google Scholar
• Ghidini M, Fusco N, Salati M, et al. The emergence of immune-checkpoint inhibitors in colorectal cancer therapy. Curr Drug Targets. 2021;22(9):1021–1033. doi:10.2174/1389450122666210204204415
   PubMed Web of Science ®Google Scholar
• Ding S, Han L. Newborn screening for genetic disorders: current status and prospects for the future. Pediatr Investig. 2022;6(4):291–298. doi:10.1002/ped4.12343
   PubMedGoogle Scholar
• Zheng Y, Li Y, Feng J, et al. Cellular based immunotherapy for primary liver cancer. J Exp Clin Cancer Res. 2021;40(1):250. doi:10.1186/s13046-021-02030-5
   PubMed Web of Science ®Google Scholar
• Xu YP, Zhou YQ, Zhao YJ, et al. High level of CD73 predicts poor prognosis of intrahepatic cholangiocarcinoma. J Cancer. 2021;12(15):4655–4660. doi:10.7150/jca.51038
   PubMed Web of Science ®Google Scholar
• Amodio V, Lamba S, Chila R, et al. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance. Cancer Cell. 2022;41:196–209.e5. doi:10.1016/j.ccell.2022.12.003
   PubMed Web of Science ®Google Scholar
• Caglayan M, Wilson SH. Pol mu dGTP mismatch insertion opposite T coupled with ligation reveals promutagenic DNA repair intermediate. Nat Commun. 2018;9(1):4213. doi:10.1038/s41467-018-06700-5
   PubMedGoogle Scholar
• Baretti M, Le DT. DNA mismatch repair in cancer. Pharmacol Ther. 2018;189:45–62. doi:10.1016/j.pharmthera.2018.04.004
   PubMed Web of Science ®Google Scholar
• Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006;7(5):335–346. doi:10.1038/nrm1907
   PubMed Web of Science ®Google Scholar
• Olave MC, Graham RP. Mismatch repair deficiency: the what, how and why it is important. Genes Chromosomes Cancer. 2022;61(6):314–321. doi:10.1002/gcc.23015
   PubMed Web of Science ®Google Scholar
• Gemelli M, Cortinovis DL, Baggi A, et al. Immune checkpoint inhibitors in malignant pleural mesothelioma: a systematic review and meta-analysis. Cancers. 2022;14(24):6063. doi:10.3390/cancers14246063
   PubMed Web of Science ®Google Scholar
• Ren B, Shen J, Qian Y, Zhou T. Sarcopenia as a determinant of the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: a meta-analysis. Nutr Cancer. 2022;1–11. doi:10.1080/01635581.2022.2153879
   Web of Science ®Google Scholar
• Jacoberger-Foissac C, Allard B, Allard D, Stagg J. Assessing the efficacy of immune checkpoint inhibitors in preclinical tumor models. Methods Mol Biol. 2023;2614:151–169. doi:10.1007/978-1-0716-2914-7_11
   PubMedGoogle Scholar
• Waissengrin B, Leshem Y, Taya M, et al. The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: a sigh of relief? Eur J Cancer. 2022;180:52–61. doi:10.1016/j.ejca.2022.11.022
   PubMed Web of Science ®Google Scholar
• Roccuzzo G, Giordano S, Fava P, et al. Immune check point inhibitors in primary cutaneous T-cell lymphomas: biologic rationale, clinical results and future perspectives. Front Oncol. 2021;11:733770. doi:10.3389/fonc.2021.733770
   PubMed Web of Science ®Google Scholar
• Hernaez R, Avila MA. Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono? Gut. 2022. doi:10.1136/gutjnl-2022-327132
   Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–3895. doi:10.1002/j.1460-2075.1992.tb05481.x
   PubMed Web of Science ®Google Scholar
• Makaremi S, Asadzadeh Z, Hemmat N, et al. Immune checkpoint inhibitors in colorectal cancer: challenges and future prospects. Biomedicines. 2021;9(9):1075. doi:10.3390/biomedicines9091075
   PubMed Web of Science ®Google Scholar
• Gessani S, Belardelli F. Immune dysfunctions and immunotherapy in colorectal cancer: the role of dendritic cells. Cancers. 2019;11(10):1491. doi:10.3390/cancers11101491
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan6733
   PubMed Web of Science ®Google Scholar
• Diaz LA Jr, Le DT. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;373(20):1979. doi:10.1056/NEJMc1510353
   PubMed Web of Science ®Google Scholar
• Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017;28(5):1036–1041. doi:10.1093/annonc/mdx029
   PubMed Web of Science ®Google Scholar
• O’Neil BH, Wallmark JM, Lorente D, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One. 2017;12(12):e0189848. doi:10.1371/journal.pone.0189848
   PubMed Web of Science ®Google Scholar
• Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11–19. doi:10.1200/JCO.19.02107
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–359. doi:10.6004/jnccn.2021.0012
   PubMed Web of Science ®Google Scholar
• Andre T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218. doi:10.1056/NEJMoa2017699
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–1191. doi:10.1016/S1470-2045(17)30422-9
   PubMed Web of Science ®Google Scholar
• Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 2020;6(11):1766–1772. doi:10.1001/jamaoncol.2020.4515
   PubMed Web of Science ®Google Scholar
• Andre TBD, Curigliano G, Curigliano G. Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study. J Clin Oncol. 2021;39(suppl3):9. doi:10.1200/JCO.2021.39.3_suppl.9
   Google Scholar
• Bhamidipati D, Raghav KPS, Morris VK, et al. Prognostic role of systemic inflammatory markers in patients with metastatic MSI-h/dMMR colorectal cancer receiving immunotherapy. J Clin Oncol. 2022;40(16_suppl):3524. doi:10.1200/JCO.2022.40.16_suppl.3524
   Web of Science ®Google Scholar
• Golstein P. Cytolytic T-cell melodrama. Nature. 1987;327(6117):12. doi:10.1038/327012a0
   PubMed Web of Science ®Google Scholar
• Mak TW. Gaining insights into the ontogeny and activation of T cells through the use of gene-targeted mutant mice. J Inflamm. 1995;45(2):79–84.
   PubMedGoogle Scholar
• Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers. 2021;13(6):1440. doi:10.3390/cancers13061440
   PubMed Web of Science ®Google Scholar
• Michelson DA, Benoist C, Mathis D. CTLA-4 on thymic epithelial cells complements Aire for T cell central tolerance. Proc Natl Acad Sci U S A. 2022;119(48):e2215474119. doi:10.1073/pnas.2215474119
   PubMed Web of Science ®Google Scholar
• Janman D, Hinze C, Kennedy A, et al. Regulation of CTLA-4 recycling by LRBA and Rab11. Immunology. 2021;164(1):106–119. doi:10.1111/imm.13343
   PubMed Web of Science ®Google Scholar
• Horzum U, Yanik H, Taskiran EZ, Esendagli G. Effector Th1 cells under PD-1 and CTLA-4 checkpoint blockade abrogate the upregulation of multiple inhibitory receptors and by-pass exhaustion. Immunology. 2022;167(4):640–650. doi:10.1111/imm.13560
   PubMed Web of Science ®Google Scholar
• Fox TA, Houghton BC, Petersone L, et al. Therapeutic gene editing of T cells to correct CTLA-4 insufficiency. Sci Transl Med. 2022;14(668):eabn5811. doi:10.1126/scitranslmed.abn5811
   PubMed Web of Science ®Google Scholar
• Berezhnoy A, Sumrow BJ, Stahl K, et al. Development and preliminary clinical activity of PD-1-guided CTLA-4 blocking bispecific DART molecule. Cell Rep Med. 2020;1(9):100163. doi:10.1016/j.xcrm.2020.100163
   PubMedGoogle Scholar
• Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20(11):1425–1434. doi:10.1038/s41590-019-0512-0
   PubMed Web of Science ®Google Scholar
• Abunasser AAA, Xue J, Balawi EJA, Zhu Y. Combination of the EP and anti-PD-1 pathway or anti-CTLA-4 for the phase III trial of small-cell lung cancer: a meta-analysis. J Oncol. 2021;2021:6662344. doi:10.1155/2021/6662344
   PubMed Web of Science ®Google Scholar
• Bredin P, Naidoo J. The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. Cancer Metastasis Rev. 2022;41(2):347–366. doi:10.1007/s10555-022-10039-1
   PubMed Web of Science ®Google Scholar
• Zhang R, Peng X, Lin J, et al. The role of SREC-I in innate immunity to aspergillus fumigatus keratitis. Invest Ophthalmol Vis Sci. 2021;62(9):12. doi:10.1167/iovs.62.9.12
   Web of Science ®Google Scholar
• Peng XD, Zhao GQ, Lin J, et al. Fungus induces the release of IL-8 in human corneal epithelial cells, via Dectin-1-mediated protein kinase C pathways. Int J Ophthalmol. 2015;8(3):441–447. doi:10.3980/j.issn.2222-3959.2015.03.02
   PubMed Web of Science ®Google Scholar
• Garralda E, Sukari A, Lakhani NJ, et al. A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. J Clin Oncol. 2021;39(15_suppl):3584. doi:10.1200/JCO.2021.39.15_suppl.3584
   Web of Science ®Google Scholar
• Huang S, Zhao Y, Liao P, et al. Different expression patterns of Vista concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma. Front Oncol. 2022;12:1014904. doi:10.3389/fonc.2022.1014904
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang Y, Wang B, et al. Blood clot scaffold loaded with liposome vaccine and siRNAs targeting PD-L1 and TIM-3 for effective DC activation and cancer immunotherapy. ACS Nano. 2022. doi:10.1021/acsnano.2c10797
   Web of Science ®Google Scholar
• Brauneck F, Fischer B, Witt M, et al. TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis. J Immunother Cancer. 2022;10(12). doi:10.1136/jitc-2022-004794
   PubMed Web of Science ®Google Scholar
• Wiede F, Lu KH, Du X, et al. PTP1B is an intracellular checkpoint that limits T-cell and CAR T-cell antitumor immunity. Cancer Discov. 2022;12(3):752–773. doi:10.1158/2159-8290.CD-21-0694
   PubMed Web of Science ®Google Scholar
• Geuijen C, Tacken P, Wang LC, et al. A human CD137xPD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade. Nat Commun. 2021;12(1):4445. doi:10.1038/s41467-021-24767-5
   PubMed Web of Science ®Google Scholar
• Keck JG, He W, Buetow BS, et al. Validation of a clinically relevant humanized mouse model for the safety assessment of 4-1BB agonists utomilumab and urelumab. J Clin Oncol. 2022;40(16_suppl):e14602–e14602. doi:10.1200/JCO.2022.40.16_suppl.e14602
   Web of Science ®Google Scholar
• Crupi MJF, Taha Z, Janssen TJA, et al. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer. Front Immunol. 2022;13:1029269. doi:10.3389/fimmu.2022.1029269
   PubMed Web of Science ®Google Scholar
• Abedi Kiasari B, Abbasi A, Ghasemi Darestani N, et al. Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): a new era in tumor immunotherapy. Int Immunopharmacol. 2022;113(PtA):109365. doi:10.1016/j.intimp.2022.109365
   PubMedGoogle Scholar
• Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17(3):299–308. doi:10.1016/S1470-2045(15)00544-6
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Van Cutsem E, Luisa Limon M, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II checkmate 142 study. J Clin Oncol. 2022;40(2):161–170. doi:10.1200/JCO.21.01015
   PubMed Web of Science ®Google Scholar
• Abdullaev S, André T, Lei M, et al. A phase III study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): checkmate 8HW. J Clin Oncol. 2020;38(4_suppl):TPS266–TPS266. doi:10.1200/JCO.2020.38.4_suppl.TPS266
   Web of Science ®Google Scholar
• Sinicrope FA, Ou F-S, Zemla T, et al. Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502). J Clin Oncol. 2019;37(15_suppl):e15169–e15169. doi:10.1200/JCO.2019.37.15_suppl.e15169
   Web of Science ®Google Scholar
• Lau D, Cunningham D, Gillbanks A, et al. POLEM: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—A phase III randomized study. J Clin Oncol. 2019;37(15_suppl):TPS3615–TPS3615. doi:10.1200/JCO.2019.37.15_suppl.TPS3615
   Web of Science ®Google Scholar
• Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566–576. doi:10.1038/s41591-020-0805-8
   PubMed Web of Science ®Google Scholar
• Yuki S, Bando H, Tsukada Y, et al. Short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. J Clin Oncol. 2020;38(15_suppl):4100. doi:10.1200/JCO.2020.38.15_suppl.4100
   Web of Science ®Google Scholar
• Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363–2376. doi:10.1056/NEJMoa2201445
   PubMed Web of Science ®Google Scholar
• Verschoor YL, Berg JVD, Beets G, et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: final clinical analysis of the NICHE study. J Clin Oncol. 2022;40(16_suppl):3511. doi:10.1200/JCO.2022.40.16_suppl.3511
   Web of Science ®Google Scholar
• Chen L, Jiang X, Li Y, et al. How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC. Clin Immunol. 2022;237:108962. doi:10.1016/j.clim.2022.108962
   PubMed Web of Science ®Google Scholar
• Moretto R, Elliott A, Zhang J, et al. Homologous recombination deficiency alterations in colorectal cancer: clinical, molecular, and prognostic implications. J Natl Cancer Inst. 2022;114(2):271–279. doi:10.1093/jnci/djab169
   PubMedGoogle Scholar
• Wang D, Zhang H, Xiang T, Wang G. Clinical application of adaptive immune therapy in MSS colorectal cancer patients. Front Immunol. 2021;12:762341. doi:10.3389/fimmu.2021.762341
   PubMed Web of Science ®Google Scholar
• Baraibar I, Mirallas O, Saoudi N, et al. Combined treatment with immunotherapy-based strategies for MSS Metastatic Colorectal Cancer. Cancers. 2021;13(24):6311. doi:10.3390/cancers13246311
   PubMed Web of Science ®Google Scholar
• Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375. doi:10.1038/s41575-019-0126-x
   PubMed Web of Science ®Google Scholar
• Borelli B, Antoniotti C, Carullo M, Germani MM, Conca V, Masi G. Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) patients beyond microsatellite instability. Cancers. 2022;14(20):4974. doi:10.3390/cancers14204974
   PubMed Web of Science ®Google Scholar
• Li Y, Ma Y, Wu Z, et al. Tumor mutational burden predicting the efficacy of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis. Front Immunol. 2021;12:751407. doi:10.3389/fimmu.2021.751407
   PubMed Web of Science ®Google Scholar
• Huang K, Lin B, Liu J, et al. Predicting colorectal cancer tumor mutational burden from histopatholog ical images and clinical information using multi-modal deep learning. Bioinformatics. 2022;38(22):5108–5115. doi:10.1093/bioinformatics/btac641
   PubMed Web of Science ®Google Scholar
• Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325–340. doi:10.1038/nrclinonc.2018.29
   PubMed Web of Science ®Google Scholar
• Kim CW, Chon HJ, Kim C. Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer. Cancers. 2021;13(19):4906. doi:10.3390/cancers13194906
   PubMed Web of Science ®Google Scholar
• Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38(18):2053–2061. doi:10.1200/JCO.19.03296
   PubMed Web of Science ®Google Scholar
• Li J, Cong L, Liu J, et al. The efficacy and safety of regorafenib in combination with anti-PD-1 antibody in refractory microsatellite stable metastatic colorectal cancer: a retrospective study. Front Oncol. 2020;10:594125. doi:10.3389/fonc.2020.594125
   PubMed Web of Science ®Google Scholar
• Cousin S, Cantarel C, Guegan JP, et al. Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. Eur J Cancer. 2022;162:161–169. doi:10.1016/j.ejca.2021.11.012
   PubMed Web of Science ®Google Scholar
• Cousin S, Cantarel C, Guegan JP, et al. Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial. Clin Cancer Res. 2021;27(8):2139–2147. doi:10.1158/1078-0432.CCR-20-3416
   PubMed Web of Science ®Google Scholar
• Wang F, He MM, Yao YC, et al. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. Cell Rep Med. 2021;2(9):100383. doi:10.1016/j.xcrm.2021.100383
   PubMedGoogle Scholar
• Cousin S, Bellera CA, Guégan JP, et al. REGOMUNE: a phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort. J Clin Oncol. 2020;38(15_suppl):4019. doi:10.1200/JCO.2020.38.15_suppl.4019
   PubMedGoogle Scholar
• Akin Telli T, Bregni G, Vanhooren M, Saude Conde R, Hendlisz A, Sclafani F. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer. Cancer Treat Rev. 2022;110:102460. doi:10.1016/j.ctrv.2022.102460
   PubMed Web of Science ®Google Scholar
• Gomez⁃Roca C, Yanez Ruiz E, Im S. LEAP-005: aphase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—results from the colorectal cancer cohort. J Clin Oncol. 2021;39(Suppl15):abstr3564. doi:10.1200/JCO.2021.39.15_suppl.3564
   Google Scholar
• Mettu NB, Twohy E, Ou FS, et al. BACCI: a phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): an ACCRU network study - ScienceDirect. Annals Oncol. 2019;30:v203.
   Web of Science ®Google Scholar
• Cremolini C, Rossini D, Antoniotti C. FOLFOXIRIplus bevacizumab(Bev) plus atezolizumab(Atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer(mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO. Ann Oncol. 2021;32(Suppl 5):S1283–S1346. doi:10.1016/j.annonc.2021.08.2094
   Google Scholar
• Zhou LN, Feng CX, Zhang Y, et al. The bevacizumab plus oxaliplatin-based chemotherapy regimen is more suitable for metastatic colorectal cancer patients with a history of schistosomiasis: a clinical retrospective analysis. J Gastrointest Oncol. 2022;13(3):1086–1096. doi:10.21037/jgo-22-207
   PubMed Web of Science ®Google Scholar
• Wang F, Dai G, Deng Y, et al. Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: a prospective, multicenter, observational, non-interventional Phase IV trial. Chin J Cancer Res. 2021;33(4):490–499. doi:10.21147/j.issn.1000-9604.2021.04.06
   PubMed Web of Science ®Google Scholar
• Dell’Aquila E, Rossini D, Fulgenzi CAM, et al. Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials. ESMO Open. 2022;7(6):100606. doi:10.1016/j.esmoop.2022.100606
   PubMed Web of Science ®Google Scholar
• Guo Y, Zhang W, Ying J, Zhang Y, Li J. Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer. J Clin Oncol. 2021;39(15_suppl):2514. doi:10.1200/JCO.2021.39.15_suppl.2514
   Web of Science ®Google Scholar
• Bai Y, Xu N, An S, Chen W, Gao C, Zhang D. A phase ib trial of assessing the safety and preliminary efficacy of a combination therapy of geptanolimab (GB 226) plus fruquintinib in patients with metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;39(15_suppl):e15551–e15551. doi:10.1200/JCO.2021.39.15_suppl.e15551
   Web of Science ®Google Scholar
• Sturrock M, Miller IS, Kang G, et al. Anti-angiogenic drug scheduling optimisation with application to colorectal cancer. Sci Rep. 2018;8(1):11182. doi:10.1038/s41598-018-29318-5
   PubMedGoogle Scholar
• Lai E, Cascinu S, Scartozzi M. Are all anti-angiogenic drugs the same in the treatment of second-line metastatic colorectal cancer? Expert opinion on clinical practice. Front Oncol. 2021;11:637823. doi:10.3389/fonc.2021.637823
   PubMed Web of Science ®Google Scholar
• Cao M, Wang Y, Lu G, et al. Classical angiogenic signaling pathways and novel anti-angiogenic strategies for colorectal cancer. Curr Issues Mol Biol. 2022;44(10):4447–4471. doi:10.3390/cimb44100305
   PubMed Web of Science ®Google Scholar
• Doleschal B, Petzer A, Rumpold H. Current concepts of anti-EGFR targeting in metastatic colorectal cancer. Front Oncol. 2022;12:1048166. doi:10.3389/fonc.2022.1048166
   PubMedGoogle Scholar
• Chu J, Fang X, Sun Z, et al. Non-coding RNAs regulate the resistance to anti-EGFR therapy in colorectal cancer. Front Oncol. 2021;11:801319. doi:10.3389/fonc.2021.801319
   PubMed Web of Science ®Google Scholar
• Park YL, Kim HP, Ock CY, et al. EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer. Oncogene. 2022;41(14):2026–2038. doi:10.1038/s41388-021-01920-4
   PubMed Web of Science ®Google Scholar
• Janani B, Vijayakumar M, Priya K, et al. EGFR-based targeted therapy for colorectal cancer-promises and challenges. Vaccines. 2022;10(4). doi:10.3390/vaccines10040499
   Web of Science ®Google Scholar
• Zhang W, Han X, Yang L, et al. Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study. BMC Cancer. 2022;22(1):1104. doi:10.1186/s12885-022-10147-9
   PubMed Web of Science ®Google Scholar
• Lee MS, Loehrer PJ, Imanirad I, et al. Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;39(3_suppl):7. doi:10.1200/JCO.2021.39.3_suppl.7
   PubMed Web of Science ®Google Scholar
• Stein A, Binder M, Goekkurt E, et al. Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): final results of the phase II AVETUX trial (AIO-KRK-0216). J Clin Oncol. 2020;38(4_suppl):96. doi:10.1200/JCO.2020.38.4_suppl.96
   Google Scholar
• Boland PM, Hutson A, Maguire O, Minderman H, Fountzilas C, Iyer RV. A phase Ib/II study of cetuximab and pembrolizumab in RAS-wt mCRC. J Clin Oncol. 2018;36(4_suppl):834. doi:10.1200/JCO.2018.36.4_suppl.834
   Google Scholar
• Cooper ZA, Reuben A, Austin-Breneman J, Wargo JA. Does it MEK a difference? Understanding immune effects of targeted therapy. Clin Cancer Res. 2015;21(14):3102–3104. doi:10.1158/1078-0432.CCR-15-0363
   PubMed Web of Science ®Google Scholar
• Goldman C, Tchack J, Robinson EM, et al. Outcomes in melanoma patients treated with BRAF/MEK-directed therapy or immune checkpoint inhibition stratified by clinical trial versus standard of care. Oncology. 2017;93(3):164–176. doi:10.1159/000475715
   PubMed Web of Science ®Google Scholar
• Buhle A, Johnson N, Grider D, Phillips M. Early onset drug-induced hypersensitivity syndrome with lymphopenia, hepatitis, and normal eosinophils induced by BRAF/MEK inhibitor after immune checkpoint inhibitor therapy. Dermatol Online J. 2022;28(1). doi:10.5070/D328157062
   Google Scholar
• Schröder C, Lawrance M, Li C, et al. Building external control arms from patient-level electronic health record data to replicate the randomized IMblaze370 control arm in metastatic colorectal cancer. JCO Clin Cancer Infor. 2021;(5):450–458. doi:10.1200/cci.20.00149
   PubMedGoogle Scholar
• Schuch G, Kobold S, Bokemeyer C. Evolving role of cetuximab in the treatment of colorectal cancer. Cancer Manag Res. 2009;1:79–88. doi:10.2147/CMAR.S4750
   PubMedGoogle Scholar
• Bendell JC, Kopetz S, Middleton MR, et al. Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation. J Clin Oncol. 2018;36(4_suppl):TPS870–TPS870. doi:10.1200/JCO.2018.36.4_suppl.TPS870
   Web of Science ®Google Scholar
• Ou SI, Janne PA, Leal TA, et al. First-in-human phase I/IB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS(G12C) solid tumors (KRYSTAL-1). J Clin Oncol. 2022;40(23):2530–2538. doi:10.1200/JCO.21.02752
   PubMed Web of Science ®Google Scholar
• Corcoran R, Giannakis M, Allen J. SO-26 Clinical efficacy of combined BRAF, MEK, and PD −1 inhibition in BRAFV600E colorectal cancer patients. Ann Oncol. 2020;31:S226–S227. doi:10.1016/j.annonc.2020.04.041
   Web of Science ®Google Scholar
• Xu T, Wang X, Xin Y, et al. Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: a phase II single-arm study and exploratory biomarker analysis. Cancer Res Treat. 2022;55:626–635. doi:10.4143/crt.2022.1058
   PubMed Web of Science ®Google Scholar
• Strickler JH, Ng K, Cercek A, et al. MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress). J Clin Oncol. 2021;39(3_suppl):TPS153–TPS153. doi:10.1200/JCO.2021.39.3_suppl.TPS153
   Google Scholar
• Suh K, Carlson JJ, Xia F, Williamson TE, Sullivan SD. The potential long-term comparative effectiveness of larotrectinib versus entrectinib for treatment of metastatic TRK fusion colorectal cancer. J Clin Oncol. 2022;40(4_suppl):40. doi:10.1200/JCO.2022.40.4_suppl.040
   PubMed Web of Science ®Google Scholar
• Yamada N, Karasawa T, Wakiya T, et al. Iron overload as a risk factor for hepatic ischemia-reperfusion injury in liver transplantation: potential role of ferroptosis. Am J Transplant. 2020;20(6):1606–1618. doi:10.1111/ajt.15773
   PubMed Web of Science ®Google Scholar
• Anne H, Harme H, Kersten C. Repeat sequential oxaliplatin⁃based chemotherapy (FLOX) and nivolumab versus FLOX alone as first⁃line treatment of microsatellite⁃stable (MSS) metastatic colorectal cancer (mCRC): initial results from the randomized METIMMOX study. J Clin Oncol. 2021;39(Suppl15):abstr3556. doi:10.1200/JCO.2021.39.15_suppl.3556
   Google Scholar
• Tabernero J, Grothey A, Arnold D. Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal⁃seeking trial of fluoropyrimidine + bevacizumab ± atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer. J Clin Oncol. 2021;39(Suppl 15):S3570. doi:10.1200/JCO.2021.39.15_suppl.3570
   Web of Science ®Google Scholar
• Xue M, Tian Y, Sui Y, et al. Protective effect of fucoidan against iron overload and ferroptosis-induced liver injury in rats exposed to alcohol. Bio Pharmaco. 2022;153:113402. doi:10.1016/j.biopha.2022.113402
   Google Scholar
• Voronova V, Vislobokova A, Mutig K, et al. Combination of immune checkpoint inhibitors with radiation therapy in cancer: a hammer breaking the wall of resistance. Front Oncol. 2022;12:1035884. doi:10.3389/fonc.2022.1035884
   PubMedGoogle Scholar
• Parikh AR, Clark JW, Wo JY-L, et al. A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC). J Clin Oncol. 2019;37(15_suppl):3514. doi:10.1200/JCO.2019.37.15_suppl.3514
   Web of Science ®Google Scholar
• Salvatore L, Bensi M, Corallo S, et al. Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): the AVANA study. J Clin Oncol. 2021;39(15_suppl):3511. doi:10.1200/JCO.2021.39.15_suppl.3511
   Web of Science ®Google Scholar
• Tamberi S, Grassi E, Zingaretti C, et al. A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results. J Clin Oncol. 2022;40(17_suppl):LBA3513–LBA3513. doi:10.1200/JCO.2022.40.17_suppl.LBA3513
   Web of Science ®Google Scholar
• Michael M, Wong R, Gill SS, et al. Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: the Ave-Rec trial. J Clin Oncol. 2019;37(15_suppl):TPS3622–TPS3622. doi:10.1200/JCO.2019.37.15_suppl.TPS3622
   Web of Science ®Google Scholar
• Wu Q, Hu X, Zhang X, et al. Single-cell transcriptomics of peripheral blood reveals anti-tumor systemic immunity induced by oncolytic virotherapy. Theranostics. 2022;12(17):7371–7389. doi:10.7150/thno.74075
   PubMed Web of Science ®Google Scholar
• Nelson A, Gebremeskel S, Lichty BD, Johnston B. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression. J Immunother Cancer. 2022;10(3). doi:10.1136/jitc-2021-003923
   Web of Science ®Google Scholar
• Svensson-Arvelund J, Cuadrado-Castano S, Pantsulaia G, et al. Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity. Nat Commun. 2022;13(1):7149. doi:10.1038/s41467-022-34791-8
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2018;174(4):1031–1032. doi:10.1016/j.cell.2018.07.035
   PubMed Web of Science ®Google Scholar
• Monge B MC, Xie C, Steinberg SM, et al. A phase I/II study of Pexa-Vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer. J Clin Oncol. 2020;38(4_suppl):117. doi:10.1200/JCO.2020.38.4_suppl.117
   Web of Science ®Google Scholar
• Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17(11):3520–3526. doi:10.1158/1078-0432.CCR-10-3126
   PubMed Web of Science ®Google Scholar
• de Weger VA, Turksma AW, Voorham QJ, et al. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer. Clin Cancer Res. 2012;18(3):882–889. doi:10.1158/1078-0432.CCR-11-1716
   PubMed Web of Science ®Google Scholar
• Uyl-de Groot CA, Vermorken JB, Hanna MG Jr, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine. 2005;23(17–18):2379–2387. doi:10.1016/j.vaccine.2005.01.015
   PubMed Web of Science ®Google Scholar
• Hubbard JM, Cremolini C, Graham RP, et al. A phase I study of PolyPEPI1018 vaccine plus maintenance therapy in patients with metastatic colorectal cancer with a predictive biomarker (OBERTO). J Clin Oncol. 2019;37(15_suppl):3557. doi:10.1200/JCO.2019.37.15_suppl.3557
   Google Scholar
• Hubbard JM, Cremolini C, Graham RP, et al. Evaluation of safety, immunogenicity, and preliminary efficacy of PolyPEPI1018 off-the-shelf vaccine with fluoropyrimidine/bevacizumab maintenance therapy in metastatic colorectal cancer (mCRC) patients. J Clin Oncol. 2020;38(15_suppl):4048. doi:10.1200/JCO.2020.38.15_suppl.4048
   Web of Science ®Google Scholar
• O’Leary K. CAR T cells beyond cancer. Nat Med. 2022;28(12):2450. doi:10.1038/s41591-022-02150-1
   Web of Science ®Google Scholar
• Bailey SR, Berger TR, Graham C, Larson RC, Maus MV. Four challenges to CAR T cells breaking the glass ceiling. Eur J Immunol. 2022;e2250039. doi:10.1002/eji.202250039
   PubMed Web of Science ®Google Scholar
• Ghazi B, El Ghanmi A, Kandoussi S, Ghouzlani A, Badou A. CAR T-cells for colorectal cancer immunotherapy: ready to go? Front Immunol. 2022;13:978195. doi:10.3389/fimmu.2022.978195
   PubMedGoogle Scholar
• Wang L, Zhang G, Shen J, Shen Y, Cai G, Liu Y. Elevated CEA and CA 19-9 levels within the normal ranges increase the likelihood of CRC recurrence in the Chinese han population. Appl Bionics Biomech. 2022;2022:8666724. doi:10.1155/2022/8666724
   PubMed Web of Science ®Google Scholar
• Koyel B, Priyabrata D, Rittwika B, et al. Deterministic role of CEA and MSI status in predicting outcome of CRC patients: a perspective study amongst hospital attending Eastern Indian Populations. Indian J Surg Oncol. 2017;8(4):462–468. doi:10.1007/s13193-017-0651-4
   PubMedGoogle Scholar
• Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3):620–626. doi:10.1038/mt.2010.272
   PubMed Web of Science ®Google Scholar
• Katz SC, Burga RA, McCormack E, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res. 2015;21(14):3149–3159. doi:10.1158/1078-0432.CCR-14-1421
   PubMed Web of Science ®Google Scholar
• Prenen H, Dekervel J, Hendlisz A, et al. Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC. J Clin Oncol. 2021;39(3_suppl):74. doi:10.1200/JCO.2021.39.3_suppl.74
   Web of Science ®Google Scholar
• Cui J, Chen N, Pu C, et al. A phase 1 dose-escalation study of GCC19 CART a novel coupled CAR therapy for subjects with metastatic colorectal cancer. J Clin Oncol. 2022;40(16_suppl):3582. doi:10.1200/JCO.2022.40.16_suppl.3582
   Google Scholar
• Morse MA, Hochster H, Benson A. Perspectives on treatment of metastatic colorectal cancer with immune checkpoint inhibitor therapy. Oncologist. 2020;25(1):33–45. doi:10.1634/theoncologist.2019-0176
   PubMed Web of Science ®Google Scholar
• Peng X, Zhao G, Lin J, Qu J, Zhang Y, Li C. Phospholipase Cgamma2 is critical for Ca(2+) flux and cytokine production in anti-fungal innate immunity of human corneal epithelial cells. BMC Ophthalmol. 2018;18(1):170. doi:10.1186/s12886-018-0847-6
   PubMedGoogle Scholar
• Dai W, Li Y, Sun W, et al. Silencing of OGDHL promotes liver cancer metastasis by enhancing hypoxia inducible factor 1 alpha protein stability. Cancer Sci. 2022. doi:10.1111/cas.15540
   Web of Science ®Google Scholar
• Yorita N, Yuge R, Takigawa H, et al. Stromal reaction inhibitor and immune-checkpoint inhibitor combination therapy attenuates excluded-type colorectal cancer in a mouse model. Cancer Lett. 2021;498:111–120. doi:10.1016/j.canlet.2020.10.041
   PubMed Web of Science ®Google Scholar